Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy.
Kevin A. Hay,Kevin A. Hay,Jordan Gauthier,Alexandre V. Hirayama,Jenna M. Voutsinas,Qian Wu,Daniel Li,Ted Gooley,Sindhu Cherian,Xueyan Chen,Barbara S. Pender,Reed M. Hawkins,Aesha Vakil,Rachel N. Steinmetz,Gary Schoch,Aude G. Chapuis,Aude G. Chapuis,Brian G. Till,Brian G. Till,Hans-Peter Kiem,Hans-Peter Kiem,Jorge Ramos,Jorge Ramos,Mazyar Shadman,Mazyar Shadman,Ryan D. Cassaday,Ryan D. Cassaday,Utkarsh Acharya,Utkarsh Acharya,Stanley R. Riddell,Stanley R. Riddell,David G. Maloney,David G. Maloney,Cameron J. Turtle,Cameron J. Turtle +34 more
Reads0
Chats0
TLDR
Patients with relapsed/refractory B-ALL enrolled in a phase 1/2 clinical trial evaluating lymphodepletion chemotherapy followed by CD19 CAR T-cell therapy who might benefit from consolidation strategies such as allogeneic HCT are studied.About:
This article is published in Blood.The article was published on 2019-04-11 and is currently open access. It has received 249 citations till now. The article focuses on the topics: Chimeric Antigen Receptor T-Cell Therapy.read more
Citations
More filters
Journal ArticleDOI
Management of adults and children undergoing chimeric antigen receptor T-cell therapy: best practice recommendations of the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE)
Ibrahim Yakoub-Agha,Christian Chabannon,Peter Bader,Grzegorz W. Basak,Halvard Bonig,Fabio Ciceri,Selim Corbacioglu,Rafael F. Duarte,Hermann Einsele,Michael Hudecek,Marie José Kersten,Ulrike Köhl,Jürgen Kuball,Stephan Mielke,Mohamad Mohty,John Murray,Arnon Nagler,Stephen P. Robinson,Riccardo Saccardi,Fermín Sánchez-Guijo,John A. Snowden,Micha Srour,Jan Styczyński,Alvaro Urbano-Ispizua,Patrick Hayden,Nicolaus Kröger +25 more
TL;DR: These practical recommendations, prepared under the auspices of the European Society of Blood and Marrow Transplantation, relate to patient care and supply chain management under the following headings: patient eligibility, screening laboratory tests and imaging and work-up prior to leukapheresis.
Journal ArticleDOI
The Other Side of CAR T-Cell Therapy: Cytokine Release Syndrome, Neurologic Toxicity, and Financial Burden.
TL;DR: Although the clinical responses of these agents in hematologic malignancies have been very encouraging, they have also produced substantial morbidity and occasionally mortality resulting from toxicity.
Journal ArticleDOI
CAR T cells with dual targeting of CD19 and CD22 in adult patients with recurrent or refractory B cell malignancies: a phase 1 trial
Jay Y. Spiegel,Shabnum Patel,Lori Muffly,Nasheed Hossain,Jean Oak,John H. Baird,Matthew J. Frank,Parveen Shiraz,Bita Sahaf,Juliana Craig,Maria Iglesias,Sheren F. Younes,Yasodha Natkunam,Michael G. Ozawa,Eric J Yang,John S. Tamaresis,Harshini Chinnasamy,Zach Ehlinger,Warren D. Reynolds,Rachel C. Lynn,Maria Caterina Rotiroti,Nikolaos Gkitsas,Sally Arai,Laura Johnston,Robert Lowsky,Robbie G. Majzner,Everett Meyer,Robert S. Negrin,Andrew R. Rezvani,Surbhi Sidana,Judith A. Shizuru,Wen-Kai Weng,Chelsea D. Mullins,Allison P. Jacob,Ilan R. Kirsch,Magali Bazzano,Jing Zhou,Sean Mackay,Scott J. Bornheimer,Liora M. Schultz,Liora M. Schultz,Sneha Ramakrishna,Kara L. Davis,Katherine A. Kong,Nirali N. Shah,Haiying Qin,Terry J. Fry,Terry J. Fry,Steven A. Feldman,Crystal L. Mackall,David B. Miklos +50 more
TL;DR: In this article, a bispecific CAR targeting CD19 and/or CD22 (CD19-22.BB.z-CAR) was tested in a phase I clinical trial of adults with relapsed/refractory B cell acute lymphoblastic leukemia (B-ALL) and LBCL.
Journal ArticleDOI
Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells
Ana Cordeiro,Evandro D. Bezerra,Alexandre V. Hirayama,Joshua A. Hill,Joshua A. Hill,Qian Wu,Jenna M. Voutsinas,Mohamed L. Sorror,Mohamed L. Sorror,Cameron J. Turtle,Cameron J. Turtle,David G. Maloney,David G. Maloney,Merav Bar,Merav Bar +14 more
TL;DR: Most of the late events observed in this cohort were not severe and many could be related to prior or subsequent therapies, suggesting a safe long-term profile of CD19-targeted CAR-T cell immunotherapy.
Journal ArticleDOI
Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies.
Reuben Benjamin,Reuben Benjamin,Charlotte Graham,Charlotte Graham,Deborah Yallop,Agnieszka Jozwik,Agnieszka Jozwik,Oana C Mirci-Danicar,Giovanna Lucchini,Danielle Pinner,Nitin Jain,Hagop M. Kantarjian,Nicolas Boissel,Marcela V. Maus,Matthew J. Frigault,André Baruchel,Mohamad Mohty,Athos Gianella-Borradori,Florence Binlich,Svetlana Balandraud,Fabien Vitry,Elisabeth Thomas,Anne Philippe,Sylvain Fouliard,Sandra Dupouy,Ibtissam Marchiq,Maria Almena-Carrasco,Nicolas Ferry,Sylvain Arnould,Cyril Konto,Paul Veys,Waseem Qasim,Antonio Pagliuca,Ghulam J. Mufti,Piers E.M. Patten,Shireen Kassam,Stephen Devereux,Majid Kazmi,Kirsty Cuthill,Victoria Potter,Andrea Kuhnl,Victoria Metaxa,Laarni Bonganay,Orla Stewart,Rose Ellard,Lorraine Catt,Jen Lewis,Farzin Farzaneh,Jackie Chappell,Alice Mason,Vicky Chu,Alan Dunlop,Adeel Saleem,Gary Cheung,Helena Munro,Elka Giemza,Oana Ciocarlie,Jan Chu,Persis Amrolia,Kanchan Rao,Robert Chiesa,Juliana Silva,Annette Hill,Maria Finch,Lindsey Young,Harvinder Hara,Sujith Samarasinghe,Anupama Rao,Ajay Vora,Kimberley Gilmour,Christine Rivat,Clare Murphy,Gulrukh Ahsan,Rasha Said Shamsah,Jesmina James,Sarah Inglott,Gary Wright,Stuart Adams,Natalia Izotova,Marina Konopleva,William G. Wierda,Elias Jabbour,Partow Kebrieai,Emily Jones,Kara McGee,Marcela Maus,Matthew Frigault,Jami Brown,Vesselina Toncheva,Keagan Casey,Hanno Hock,Meaghan A McKeown,Richard Mathews,Thomas R. Spitzer,Emmanuel Raffoux,Etienne Lengliné,Raphael Itzykson,Florence Rabian,Jérôme Larghero,Isabelle Madelaine,Elie Azoulay,Emmanuelle Clappier,Sophie Caillat-Zucman,Martine Meunier,Karine Celli-Lebras,Marie-Thérèse Tremorin,Karima Yakouben,Françoise Mechinaud-Heloury,Audrey Grain,Aurélia Alimi,Julie Roupret,Delphine Chaillou,Hélène Cavé,Aurélie Caye-Eude,Odile Fenneteau,Elodie Lainey,Jérôme Naudin,Eolia Brissot,Remy Dulery,Florent Malard,Clémence Mediavilla,Agnès Bonnin,Anne Vekhoff,Tounes Ledraa,Anne Daguenel-Nguyen +124 more
TL;DR: These two studies show the feasibility of using allogeneic, genome-edited CAR T cells to treat patients with aggressive leukaemia for the first time, and UCART19 exhibited in-vivo expansion and antileukaemic activity with a manageable safety profile in heavily pretreated paediatric and adult patients with relapsed or refractory B-cell acute lymphoblasticLeukaemia.
References
More filters
Book ChapterDOI
Nonparametric Estimation from Incomplete Observations
Edward L. Kaplan,Paul Meier +1 more
TL;DR: In this article, the product-limit (PL) estimator was proposed to estimate the proportion of items in the population whose lifetimes would exceed t (in the absence of such losses), without making any assumption about the form of the function P(t).
Journal ArticleDOI
Robust Locally Weighted Regression and Smoothing Scatterplots
TL;DR: Robust locally weighted regression as discussed by the authors is a method for smoothing a scatterplot, in which the fitted value at z k is the value of a polynomial fit to the data using weighted least squares, where the weight for (x i, y i ) is large if x i is close to x k and small if it is not.
Journal ArticleDOI
Chimeric antigen receptor T cells for sustained remissions in leukemia.
Shannon L. Maude,Noelle Frey,Pamela A. Shaw,Richard Aplenc,David M. Barrett,Nancy Bunin,Anne Chew,Vanessa E. Gonzalez,Zhaohui Zheng,Simon F. Lacey,Yolanda D. Mahnke,J. Joseph Melenhorst,Susan R. Rheingold,Angela Shen,David T. Teachey,Bruce L. Levine,Carl H. June,David L. Porter,Stephan A. Grupp +18 more
TL;DR: Chimeric antigen receptor-modified T-cell therapy against CD19 was effective in treating relapsed and refractory ALL and was associated with a high remission rate, even among patients for whom stem-cell transplantation had failed, and durable remissions up to 24 months were observed.
Journal ArticleDOI
Asymptotically Efficient Rank Invariant Test Procedures
Richard Peto,Julian Peto +1 more
Journal ArticleDOI
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
Shannon L. Maude,Theodore W. Laetsch,Jochen Buechner,S. Rives,Michael Boyer,Henrique Bittencourt,Peter Bader,Michael R. Verneris,Heather E. Stefanski,G.D. Myers,Muna Qayed,B. De Moerloose,Hidefumi Hiramatsu,Krysta Schlis,Kara L. Davis,Paul L. Martin,Eneida R. Nemecek,Gregory A. Yanik,Christina Peters,André Baruchel,Nicolas Boissel,Francoise Mechinaud,Adriana Balduzzi,Joerg Krueger,Carl H. June,Bruce L. Levine,Patricia A. Wood,Tanya Taran,Mimi Leung,Karen Thudium Mueller,Yiyun Zhang,Kapildeb Sen,David Lebwohl,Michael A. Pulsipher,Stephan A. Grupp +34 more
TL;DR: In this global study of CAR T‐cell therapy, a single infusion of tisagenlecleucel provided durable remission with long‐term persistence in pediatric and young adult patients with relapsed or refractory B‐cell ALL, with transient high‐grade toxic effects.
Related Papers (5)
Tisagenlecleucel in Children and Young Adults with B-Cell Lymphoblastic Leukemia
Shannon L. Maude,Theodore W. Laetsch,Jochen Buechner,S. Rives,Michael Boyer,Henrique Bittencourt,Peter Bader,Michael R. Verneris,Heather E. Stefanski,G.D. Myers,Muna Qayed,B. De Moerloose,Hidefumi Hiramatsu,Krysta Schlis,Kara L. Davis,Paul L. Martin,Eneida R. Nemecek,Gregory A. Yanik,Christina Peters,André Baruchel,Nicolas Boissel,Francoise Mechinaud,Adriana Balduzzi,Joerg Krueger,Carl H. June,Bruce L. Levine,Patricia A. Wood,Tanya Taran,Mimi Leung,Karen Thudium Mueller,Yiyun Zhang,Kapildeb Sen,David Lebwohl,Michael A. Pulsipher,Stephan A. Grupp +34 more
T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial
Daniel W. Lee,James N. Kochenderfer,Maryalice Stetler-Stevenson,Yongzhi K Cui,Cindy Delbrook,Steven A. Feldman,Terry J. Fry,Rimas J. Orentas,Marianna Sabatino,Nirali N. Shah,Seth M. Steinberg,Dave Stroncek,Nick Tschernia,Constance M. Yuan,Hua Zhang,Ling Zhang,Steven A. Rosenberg,Alan S. Wayne,Crystal L. Mackall +18 more
Chimeric antigen receptor T cells for sustained remissions in leukemia.
Shannon L. Maude,Noelle Frey,Pamela A. Shaw,Richard Aplenc,David M. Barrett,Nancy Bunin,Anne Chew,Vanessa E. Gonzalez,Zhaohui Zheng,Simon F. Lacey,Yolanda D. Mahnke,J. Joseph Melenhorst,Susan R. Rheingold,Angela Shen,David T. Teachey,Bruce L. Levine,Carl H. June,David L. Porter,Stephan A. Grupp +18 more
CD19 CAR–T cells of defined CD4+:CD8+ composition in adult B cell ALL patients
Cameron J. Turtle,Laïla Aïcha Hanafi,Carolina Berger,Ted Gooley,Sindhu Cherian,Michael Hudecek,Daniel Sommermeyer,Katherine Melville,Barbara S. Pender,Tanya M Budiarto,Emily Robinson,Natalia N Steevens,Colette Chaney,Lorinda Soma,Xueyan Chen,Cecilia Yeung,Brent L. Wood,Daniel Li,Jianhong Cao,Shelly Heimfeld,Michael C. Jensen,Stanley R. Riddell,David G. Maloney +22 more